Navigation Links
Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth

Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE(R) 8% (progesterone gel), PROCHIEVE(R) 8%(progesterone gel), PROCHIEVE 4% (progesterone gel), and STRIANT(R) (testosterone buccal tablet) in the U.S.; the timely and successful development of new products, including the clinical and regulatory path for possible development of PROCHIEVE 8% for the prevention of preterm birth; the timely and successful completion of clinical studies; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.

CRINONE(R), PROCHIEVE(R) and STRIANT(R) are registered trademarks of Columbia Laboratories, Inc.

Contact

Columbia Laboratories, Inc.
James A. Meer, 973-486-8860
Senior Vice President, CFO & Treasurer
or
Rx Communications, LLC
Melody A. Carey, 917-322-2571
Co-President


'"/>




Page: 1 2 3

Related medicine technology :

1. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
2. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:8/21/2014)... 2014 InfinityQS International, Inc., the global ... , today announces Infusion Chicago, its 9 th ... held Oct. 9-10, 2014, at the Chicago Marriott ... the necessity for implementing a quality system that ... to gain insight into production processes. Complimentary registrations ...
(Date:8/21/2014)... , Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... applicable Reference Yields and consideration payable in connection with its ... August 7, 2014 for (1) any and all of its ... and (2) up to a maximum amount of its 6.125% ... 5.750% Senior Notes due 2017 (collectively, the "Maximum Tender Offer ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... REGENSBURG, Germany, June 2 The TGF-beta 2,inhibitor ... good safety,and tolerability in the systemic treatment of ... administered,intravenously, showed a clear proof of concept. Patients ... for seven days every other week,as second or ...
... Transplant Congress in Toronto, MIAMI, June 2 ... Departments of Surgery and Pathology at the University ... corroborated the value of,monitoring cell- mediated immunity (CMI) ... regular laboratory assay of cell function,(ImmuKnow(R)/Cylex). Their paper, ...
Cached Medicine Technology:Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 2Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 3Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma 4University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4
(Date:8/21/2014)... 21, 2014 DMG Productions announces the ... to broadcast on Monday, August 25, 2014 at 7:00 ... , In this episode, Innovations will go behind-the-scenes ... and improves human performance. Audiences will be amazed by ... spaces by installing and providing access to real musical ...
(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... San Luis Obispo, CA (PRWEB) August 21, 2014 ... July/August edition of Current Pedorthics, a bi-monthly publication of the ... the field of pedorthics. , Bunion Bootie ... as an alternative solution for bunion sufferers and their pain. ... be worn in nearly any shoe to eliminate the friction ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to a ... Academy of Ophthalmology, environmental factors may outweigh genetics in the ... 42 percent of the world’s population is nearsighted, and this ... , “This is an important finding in the field ... “Not only are we finding better ways to treat ...
(Date:8/21/2014)... Beverly Hills Medical Center of Kuwait is excited to ... a new diagnostic option for measuring tear production levels to ... TearLab is a revolutionary new testing method for dry ... amount of tears a patient produces and take the necessary ... Director at the Kuwait medical center. “The test collects a ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2
... ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. ... to developing the next,generation of therapeutic products ... candidate, Streptomycin nanoparticles,will be the subject of ... in,Treatment and Pathogenesis of Mycobacterial Infections" at ...
... Company Serves as a Free Resource to Employees Seeking Senior ... ... the nation,s largest,referral service of senior care options, was recently recognized in ... to when an,employer does not offer eldercare assistance as a part of ...
... genes can work in more powerful and sneaky ways than ... JAK that is closely related to a common cancer-causing gene ... manner. JAK disrupts the activity of an organisms DNA on ... on in an embryos development. , A team from the ...
... Hotel, Washington, D.C.,National and International Health Care Professionals will Convene to ... ... Failure Patients, WASHINGTON, Sept. 17 ... convenes Sunday, September,16, 2007 at the Marriott Wardman Park Hotel in ...
... out of 4 Slept Better on New Sleep Better(TM) ... effort to test the,connection between a new, quality bed ... townspeople of Pillow, Pa. let go of one of ... Sleep Better(TM),Project. Residents of this central Pennsylvania bedroom ...
... 16, 2007 New findings by UT Southwestern Medical ... interferes with the beneficial effects estrogen has on the ... between cholesterol and estrogen in heart disease. , The ... October issue of the journal Nature Medicine , ...
Cached Medicine News:Health News:AlphaRx To Present at 47th Annual ICAAC 2Health News:A Place for Mom, Nation's Largest Senior Care Referral Service, Fills a Gap in Employee Benefits 2Health News:If you think cancer genes are simple, you don't know JAK 2Health News:If you think cancer genes are simple, you don't know JAK 3Health News:If you think cancer genes are simple, you don't know JAK 4Health News:If you think cancer genes are simple, you don't know JAK 5Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 2Health News:Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research 3Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 2Health News:Pillow, PA's Great American Sleep Better(TM)Project Reports Results 3Health News:Cholesterol byproduct blocks heart health benefits of estrogen 2Health News:Cholesterol byproduct blocks heart health benefits of estrogen 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: